Galecto, PharmAkea Merger Creates Single Company with Strong Fibrotic Disease, Cancer Pipelines

Galecto Biotech and PharmAkea, two clinical-stage pharmaceutical companies with robust pipelines in fibrotic diseases and cancer, have merged into a single company. Following the merger, the combined company will maintain the Galecto name, as well as its current senior management team, which includes Hans Schambye as CEO. Galecto,…

Potential Therapy for IPF, PAT-1251, Seen To Be Safe and Well-Tolerated in Phase 1 Trial

A first clinical trial of the safety and tolerability of a potential treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases —  PAT-1251, being developed by PharmAkea — was successfully completed in healthy volunteers, the company announced. PAT-1251 is an investigational small-molecule designed to specifically inhibit the LOXL2 enzyme. Patients with fibrotic illnesses,…